Showing 1781-1790 of 3223 results for "".
- Prevent Blindness Announces Matt MacDonald as Chair-Elect of Board of Directorshttps://modernod.com/news/prevent-blindness-announces-matt-macdonald-as-chair-elect-of-board-of-directors/2482708/Prevent Blindness, a nonprofit organization dedicated to eye health and safety awareness, named Matt MacDonald as Chair-elect of its Board of Directors. The vote was held last week during the Spring 2025 Board Meeting. He will succeed current Board of Directors Chair Jim McGrann, CEO of Adva
- Altris AI Launches Advanced Optic Disc Analysis for Glaucomahttps://modernod.com/news/altris-ai-launches-advanced-optic-disc-analysis-for-glaucoma-complementing-gcc-asymmetry-analysis/2482683/Altris AI, a provider of AI OCT scan analysis for the detection of a range of retina pathologies and biomarkers, announced the launch of an advanced glaucoma 'Optic Disc Analysis' module. To address need to improve timely and accurate gl
- Alcon Announces US Launch of Systane PRO PF for Dry Eye Reliefhttps://modernod.com/news/alcon-announces-us-launch-of-systane-pro-pf-for-dry-eye-relief/2482678/Alcon has launched Systane PRO Preservative-Free (PF) in the US, the latest addition to its over-the-counter dry eye portfolio. According to Alcon, Systane PRO PF is the longest-lasting eye drop in the Systane lineup, offering a tr
- Alcon Announces US Launch of Voyager DSLT for Glaucoma and Ocular Hypertensionhttps://modernod.com/news/alcon-announces-us-launch-of-voyager-dslt-for-glaucoma-and-ocular-hypertension/2482669/Alcon announced the full US commercial availability of Voyager DSLT, the first and only direct selective laser trabeculoplasty device (DSLT). According to Alcon, Voyager DSLT may accelerate the adoption of laser as a first-line therapy, making the treatment availabil
- FDA Expands Label for Izervay for GA Allowing for No Limitation on Duration of Dosinghttps://modernod.com/news/fda-expands-label-for-izervay-for-ga-allowing-for-no-limitation-on-duration-of-dosing/2482665/The FDA has approved an expanded label for Astellas Pharma's geographic atrophy drug Izervay (avacincaptad pegol intravitreal solution), allowing the drug to be used without a limitation on duration of dosing. The approval, which provides physicians and pat
- Alkeus Announces Interim TEASE-3 Study Results Evaluating Gildeuretinol in Early-Stage Stargardt Patientshttps://modernod.com/news/alkeus-announces-new-interim-tease-3-study-results-showing-gildeuretinol-prevented-disease-progression-in-early-stage-stargardt-patients/2482608/Alkeus Pharmaceuticals announced positive interim data from its TEASE-3 study demonstrating that additional early-stage Stargardt disease patients treated with oral gildeuretinol acetate showed no disease progression, including stable visual acuity, over multiple years. “Thes
- Altris AI Introduces AI-Powered Fluid and GA Quantification Featureshttps://modernod.com/news/altris-ai-introduces-ai-powered-fluid-and-ga-quantification-features/2482606/Altris AI, which utilizes artificial intelligence for OCT scan analysis, has unveiled additional quantification features for fluids and geographic atrophy (GA) tracking on its web platform. Altris AI currently detects more than 70 retina pathologies and biomarkers. The platform'
- Aurion Announces Positive Topline Data for Phase 1/2 Trial of Allogeneic Cell Therapy for Corneal Edemahttps://modernod.com/news/aurion-announces-positive-topline-data-for-phase-12-trial-of-allogeneic-cell-therapy-for-corneal-edema-secondary-to-corneal-endothelial-dysfunction/2482584/Aurion Biotech announced topline data from its phase 1/2 clinical trial (CLARA) of AURN001, an allogeneic cell therapy product candidate for the treatment of corneal edema secondary to corneal endothelial dysfunction. AURN001 is a combination cell therapy product candidate comprise
- Bausch + Lomb Acquires Elios Vision to Bolster Glaucoma Surgical Portfoliohttps://modernod.com/news/bausch-lomb-acquires-elios-vision-to-bolster-glaucoma-surgical-portfolio/2482575/Bausch + Lomb announced that an affiliate has acquired Elios Vision, developer of the ELIOS procedure, a minimally invasive glaucoma surgery (MIGS) procedure using an excimer laser. Financial terms of the deal were not disclosed. According to B+
- Alcon Expands TOTAL30 for Astigmatism Offerings with New Parametershttps://modernod.com/news/alcon-expands-total30-for-astigmatism-offerings-with-new-parameters-to-enhance-comfort-and-accessibility/2482553/Alcon announced the availability of expanded parameters for TOTAL30 for Astigmatism. As the first and only monthly replacement Water Gradient toric contact lens, TOTAL30 is designed to deliver a